| Autor: |
Albanese, Luisa, Caliendo, Gemma, D’Elia, Giovanna, Passariello, Luana, Maria Molinari, Anna, Napoli, Claudio, Teresa Vietri, Maria |
| Předmět: |
|
| Zdroj: |
Journal of Circulating Biomarkers; Jan-Dec2022, Vol. 11 Issue 1, p1-4, 4p |
| Abstrakt: |
Our data confirm that intact fibroblast growth factor 23 (iFGF-23) concentration is increased in patients with chronic kidney disease (CKD) and that it increases with disease progression (stages I-V). Therefore, iFGF-23 could be considered an early biomarker in the course of chronic kidney disease-mineral bone disorder (CKD-MBD), which has several aspects that make it potentially useful in clinical practice. The availability of an automated method for iFGF-23 assay may represent an added value in the management of the patient with CKD-MBD already from the early stages of the disease, before the increase of the routinely used laboratory parameters, 1-84 parathyroid hormone (PTH) and 25-OH-vitamin D (25-OH-vitD), which occur in more advanced stages of the disease. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
